Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.
Saved in:
| Title: | Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes. |
|---|---|
| Authors: | Chow E; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Wang K; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Lim CKP; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Tsoi STF; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Fan B; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Poon E; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China., Luk AOY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China., Ma RCW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Ferrannini E; Institute of Clinical Physiology, National Research Council of Italy (CNR), Pisa, Italy., Mari A; Institute of Neuroscience, National Research Council of Italy (CNR), Padua, Italy., Chen L; Hua Medicine, Shanghai, China., Chan JCN; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China. |
| Source: | Diabetes [Diabetes] 2023 Feb 01; Vol. 72 (2), pp. 299-308. |
| Publication Type: | Randomized Controlled Trial; Journal Article |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36342518 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Chow+E%22">Chow E</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Wang+K%22">Wang K</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Lim+CKP%22">Lim CKP</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Tsoi+STF%22">Tsoi STF</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Fan+B%22">Fan B</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Poon+E%22">Poon E</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Luk+AOY%22">Luk AOY</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Ma+RCW%22">Ma RCW</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Ferrannini+E%22">Ferrannini E</searchLink>; Institute of Clinical Physiology, National Research Council of Italy (CNR), Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Mari+A%22">Mari A</searchLink>; Institute of Neuroscience, National Research Council of Italy (CNR), Padua, Italy.<br /><searchLink fieldCode="AU" term="%22Chen+L%22">Chen L</searchLink>; Hua Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Chan+JCN%22">Chan JCN</searchLink>; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220372763%22">Diabetes</searchLink> [Diabetes] 2023 Feb 01; Vol. 72 (2), pp. 299-308. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Diabetes+Association%22">American Diabetes Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372763 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1939-327X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200121797%22">00121797 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36342518 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2337/db22-0708 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 299 Titles: – TitleFull: Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chow E – PersonEntity: Name: NameFull: Wang K – PersonEntity: Name: NameFull: Lim CKP – PersonEntity: Name: NameFull: Tsoi STF – PersonEntity: Name: NameFull: Fan B – PersonEntity: Name: NameFull: Poon E – PersonEntity: Name: NameFull: Luk AOY – PersonEntity: Name: NameFull: Ma RCW – PersonEntity: Name: NameFull: Ferrannini E – PersonEntity: Name: NameFull: Mari A – PersonEntity: Name: NameFull: Chen L – PersonEntity: Name: NameFull: Chan JCN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2023 Feb 01 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1939-327X Numbering: – Type: volume Value: 72 – Type: issue Value: 2 Titles: – TitleFull: Diabetes Type: main |
| ResultId | 1 |
